Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Provexis plc

Healthcare GB PXS

1.05GBX
-0.05(4.55%)

Last update at 2026-06-05T14:48:00Z

Day Range

1.051.10
LowHigh

52 Week Range

0.451.55
LowHigh

Fundamentals

  • Previous Close 1.10
  • Market Cap22.29M
  • Volume130974
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.87M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.43M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-09-30 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-09-30 2023-03-31 2022-03-31
Income before tax -0.44964M -0.60200M -0.52148M -0.41992M -0.29913M
Minority interest 0.00000M 0.00187M 0.00000M 0.00187M 0.02M
Net income -0.45272M -0.58624M -0.49659M -0.38524M -0.22425M
Selling general administrative 0.42M 0.40M 0.38M 0.39M 0.32M
Selling and marketing expenses 0.07M 0.07M 0.06M 0.05M 0.05M
Gross profit 0.53M 0.28M 0.28M 0.29M 0.38M
Reconciled depreciation - - - - -
Ebit - -1.20718M -0.49659M -0.42093M -0.29920M
Ebitda -0.44964M -0.60359M - -0.42093M -0.29920M
Depreciation and amortization - 0.60M - - 0.02M
Non operating income net other - - - - -
Operating income -0.44832M -0.60359M -0.49659M -0.42093M -0.29920M
Other operating expenses 1.74M 1.41M 1.12M 0.81M 0.73M
Interest expense - - - 0.00007M 0.00007M
Tax provision 0.00308M -0.01388M -0.02489M -0.03280M -0.05890M
Interest income 0.00233M 0.00159M 0.00178M 0.00101M 0.00007M
Net interest income 0.00233M 0.00159M 0.00178M 0.00101M 0.00007M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00308M -0.01388M -0.02489M -0.03280M -0.05890M
Total revenue 1.29M 0.80M 0.60M 0.39M 0.43M
Total operating expenses 0.98M 0.89M 0.80M 0.72M 0.68M
Cost of revenue 0.76M 0.52M 0.32M 0.10M 0.05M
Total other income expense net 0.00233M 0.00159M -0.02489M 0.00101M 0.00007M
Discontinued operations - - - - -
Net income from continuing ops -0.45272M -0.58812M -0.49659M -0.38712M -0.24023M
Net income applicable to common shares - - - -0.38524M -0.22425M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 1.01M 0.50M 0.85M 1.13M 1.29M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.02M 0.15M 0.18M 0.18M 0.15M
Total liab 0.25M 0.31M 0.19M 0.16M 0.15M
Total stockholder equity 1.30M 0.72M 1.19M 1.50M 1.66M
Deferred long term liab - - - - -
Other current liab 0.20M 0.28M 0.17M 0.13M 0.13M
Common stock 2.35M 2.22M 2.22M 2.21M 2.21M
Capital stock 2.35M 2.22M 2.22M 2.21M 2.21M
Retained earnings -20.48121M -26.79598M -26.33079M -25.98614M -25.82901M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.71M 0.19M 0.38M 0.86M 1.08M
Cash and equivalents - - - - -
Total current liabilities 0.25M 0.31M 0.19M 0.16M 0.15M
Current deferred revenue - - - - -
Net debt -0.70809M -0.18936M -0.37912M -0.86387M -1.07741M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 19.43M 18.70M 25.30M 25.27M 25.27M
Property plant equipment - - - - -
Total current assets 1.01M 0.50M 0.85M 1.13M 1.29M
Long term investments - - - - -
Net tangible assets - - 1.19M 1.50M 1.66M
Short term investments - - - - -
Net receivables 0.08M 0.02M 0.00397M 0.12M 0.05M
Long term debt - - - - -
Inventory 0.20M 0.14M 0.33M 0.09M 0.06M
Accounts payable 0.03M 0.02M 0.02M 0.02M 0.02M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 6.60M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 2.21M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-03-31 2024-03-31 2023-09-30 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-09-30 2023-03-31 2022-03-31
Investments 0.00193M 0.00173M 0.00187M 0.00089M 0.00008M
Change to liabilities - - - 0.03M 0.00723M
Total cashflows from investing activities 0.00193M 0.00173M - 0.00089M 0.00008M
Net borrowings - - - - -
Total cash from financing activities 0.86M - - 0.04M 1.05M
Change to operating activities - - - - -
Net income -0.45272M -0.58624M -0.49659M -0.38712M -0.24023M
Change in cash 0.52M -0.18976M -1.17028M -0.48475M -0.21354M
Begin period cash flow 0.19M 0.38M 0.74M 0.86M 1.08M
End period cash flow 0.71M 0.19M -0.42573M 0.38M 0.86M
Total cash from operating activities -0.34083M -0.19150M -0.42760M -0.52074M -0.21361M
Issuance of capital stock 0.86M 0.00000M 0.00000M 0.04M 0.00000M
Depreciation - - - - -
Other cashflows from investing activities 0.00193M 0.00173M - 0.00089M 0.00008M
Dividends paid - - - - -
Change to inventory -0.06583M 0.19M -0.08190M -0.24199M -0.02523M
Change to account receivables 0.04M -0.06451M - 0.04M 0.04M
Sale purchase of stock - - - - -
Other cashflows from financing activities - 0.00173M 0.00187M 0.00089M 0.00008M
Change to netincome - - - 0.03M -0.00784M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00025M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.08998M 0.25M -0.03930M -0.16811M 0.02M
Stock based compensation 0.17M 0.12M 0.09M 0.04M 0.07M
Other non cash items 0.03M 0.03M 0.02M -0.00611M -0.05898M
Free cash flow -0.33890M -0.19150M -0.42760M -0.52074M -0.21386M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PXS
Provexis plc		 -0.05 4.55% 1.05 - - 25.58 19.98 25.65 -51.8261
HLN
Haleon PLC		 7.20 2.18% 337.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC		 11.00 0.75% 1471.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd		 -11.0 6.38% 161.50 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics		 -0.4 4.49% 8.50 - 106.38 11.72 159.47 12.12 -4.1496

Reports Covered

Stock Research & News

View All

Profile

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through e-commerce website and distributors. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

Provexis plc

2 Blagrave Street, Reading, United Kingdom, RG1 1AZ

Key Executives

Name Title Year Born
Mr. Ian Ford BA (Hons) ACA CEO, CFO, Company Sec. & Exec. Director 1966
Dr. Niamh Ann O'Kennedy B.Sc., BSc, M.Sc., MSc, Ph.D. Chief Scientific Officer, Member of Scientific Advisory Board & Exec. Director 1974
Prof. Asim K. Duttaroy BS MS Ph.D., DSc FICN Consultant & Member of Scientific Advisory Board NA
Mr. Ian Ford BA (Hons) ACA, F.C.A. CEO, CFO, Company Secretary & Executive Director 1965
Dr. Niamh Ann O'Kennedy B.Sc., M.Sc., Ph.D. Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions